New quality of life data with immune-based treatment of metastatic renal cell carcinoma

Even in a first-line setting, where patient’s aims are usually unbalanced towards better antitumor activity and efficacy, QoL remains an important endpoint to pursue. In this MEDtalk Camilo Porta, Italy, presents new Quality of Life data from ESMO 2021.